Immunovant Inc (IMVT) — Financial Flexibility Index

Latest as of December 2025: -1.39x

Immunovant Inc (IMVT) has a Financial Flexibility Index of -1.39x as of December 2025. Free cash flow of $-92.33 Million (operating CF $-92.33 Million minus capex $0.00) represents -1% of total liabilities ($66.26 Million). Check Immunovant Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Financial Flexibility Index

-1.39x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-92.33 Million
Operating CF − Capex

Total Liabilities

$66.26 Million
USD

Capital Expenditures

$0.00
USD

Immunovant Inc Financial Flexibility Index (2018–2025)

Historical Financial Flexibility Index trend for Immunovant Inc across 8 annual periods. See Immunovant Inc (IMVT) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Annual Financial Flexibility Index for Immunovant Inc (2018–2025)

Year-by-year free cash flow to debt coverage for Immunovant Inc. For the full company profile including market capitalisation, see Immunovant Inc market cap and net worth.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -5.45x $-375.12 Million $-375.87 Million $68.78 Million ▼ -24.8%
2024 -4.37x $-213.87 Million $-214.23 Million $48.95 Million ▼ -0.7%
2023 -4.34x $-188.00 Million $-188.19 Million $43.34 Million ▼ -87.4%
2022 -2.31x $-105.86 Million $-106.11 Million $45.74 Million ▲ +41.5%
2021 -3.96x $-83.12 Million $-83.33 Million $21.01 Million ▼ -13.6%
2020 -3.48x $-53.33 Million $-53.36 Million $15.32 Million ▲ +95.4%
2019 -74.90x $-28.50 Million $-28.55 Million $380.45K ▲ +6.0%
2018 -79.66x $-128.25 Million $-128.30 Million $1.61 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities